- National Cancer Institute. Targeted Cancer Therapies. 2014 November 2014; Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
- Polovich, M., J.M. White, and L.O. Kelleher, Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. 2005, Pittsburgh: Oncology Nursing Society.
- Rieger, P.T., Biotherapy, in Biotherapy: A Comprehensive Overview, P.T. Rieger, Editor. 2001, Jones and Bartlett: Sudbury. p. 3-37.
- Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674.
- Brown, M.P. and N. Burdett, Targeted therapies, aspects of pharmaceutical and oncological management. Cancer Forum, 2013. 37(1).
- Levitzki, A. and S. Klein, Signal transduction therapy of cancer. Molecular Aspects of Medicine, 2010. 31: p. 287-327.
- Liauw, W.S., Molecular mechanisms and clinical use of targeted anticancer drugs. Australian Prescriber, 2013. 36(4): p. 126-131.
- National Cancer Institute. Cancer Vaccines. 2014 November 2014; Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-vaccines.
- Polovich, M., J. Whitford, and N. Olsen, eds. Chemotherapy and biotherapy guidelines and recommendations for practice. 3rd ed. 2009, Oncology Nursing Society: Philadelphia.
- Battiato, L.A. and V.S. Wheeler, Biologic and targeted therapy, in Cancer Nursing Principles and Practice, C.H. Yarbro, D. Wujcik, and B. Holmes Gobel, Editors. 2011, Jones and Bartlett: Sudbury.
- Solomon, B. and J. Zalcberg, Overview: progress in targeted therapies for cancer. Cancer Forum, 2008. 32: p. 131-135.
- Wilkes, G.M. and M. Barton-Burke, Oncology Nursing Drug Handbook. 2010, Boston: Jones and Bartlett Publishers.
- Gobel, B.H., Hematopoietic therapy, in Cancer Nursing Principles and Practice, C.H. Yarbro, M.H. Frogge, and M. Goodman, Editors. 2011, Jones and Bartlett: Sudbury. p. 575-589.
- Schmidt, K.V. and B.A. Wood, Trends in cancer therapy: Role of monoclonal antibodies. Seminars in Oncology Nursing, 2003. 19: p. 169-179.
- Davis, I.D., Update on monoclonal antibodies for the treatment of cancer. Asia-Pacific Journal of Clinical Oncology, 2011. 7(Suppl. 1): p. 20-25.
- Gale, D.M., Molecular targets in cancer therapy. Seminars in Oncology Nursing, 2003. 19: p. 193-205.
- Boyle, F., Search for the holy grail: Evolving targeted therapies in breast cancer. Cancer Forum, 2008. 32(3): p. 159-162.
- Muehlbauer, P.M. and D.J. Schwartzentruber, Cancer vaccines. Seminars in Oncology Nursing, 2003. 19: p. 206-216.
- Smith, M., Update on HPV vaccination in Australia. Cancer Forum, 2014. 38(3): p. 207-208.
- Muehlbauer, P.M., Anti-angiogenesis in cancer therapy. Seminars in Oncology Nursing, 2003. 19: p. 180-192.
- Gasparini, G., The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs, 1999. 58(1): p. 17-38.
- Wilkes, G.M., Targeted cancer therapy: A handbook for nurses. 2011, Sudbury: Jones and Bartlett.
- Malizzia, L.J. and A. Hsu, Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clinical Journal of Oncology Nursing, 2008. 12: p. 639-646.
- Pook, D. and I.D. Davis, Targeted therapies in renal cell carcinoma. Cancer Forum, 2008. 32(3): p. 155-158.
- Stull, D.M., Targeted therapies for the treatment of leukaemia. Seminars in Oncology Nursing, 2003. 19: p. 90-97.
- National Institute for Occupational Safety and Health. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. 2004 01.05.2009; Available from: http://www.cdc.gov/niosh/docs/2004-165/.
- Alexander, M., et al., Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel. Internal Medicine Journal, 2014. 44(10): p. 1018-1026.
- Ault, P., Overview of second generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myeloid leukaemia. Clinical Journal of Oncology Nursing, 2007. 11: p. 125-129.
- Meijerman, I., J.H. Beijnen, and J.H.M. Schellens, Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction. The Oncologist, 2006. 11(7): p. 742-752.
- Lohr, L.K., Drug interactions with newer oral chemotherapy agents. US Pharmacist, 2009. 24(7 (Oncology supplement)): p. 4-8.
- Breslin, S., Cytokine release syndrome: Overview and nursing implications. Clinical Journal of Oncology Nursing, 2007. 11(Suppl.1): p. 37-42.
- Dunsford, J., Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clinical Journal of Oncology Nursing, 2008. 12: p. 405-407.
- Eaby, B., A. Culkin, and M.E. Lacouture, An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 2008. 12: p. 283-290.
- Viale, P.H. and D.S. Yamamoto, Cardiovascular toxicity associated with cancer treatment. Clinical Journal of Oncology Nursing, 2008. 12: p. 627-638.
- Goodrich, A., Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukaemia. Clinical Journal of Oncology Nursing, 2007. Suppl. 11: p. 23-36.
- Davis, I.D. and J.S. Cebon, Developing cancer immunotherapies. Asia-Pacific Journal of Clinical Oncology, 2011. 7(Suppl. 1): p. 9-13.
- Schilsky, R.L., et al., Commentary: tackling the challenges of developing targeted therapies for cancer. The Oncologist, 2010. 15: p. 484-487.
- Lord, S., C. Lee, and R.J. Simes, Role of prognostic and predictive markers in cancer. Cancer Forum, 2008. 32(3).
- Malinowsky, K., et al., Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. Journal of Cancer, 2011. 2: p. 26-35.
